Monopar Therapeutics Inc (MNPR)

Jun 03, 2025

Monopar Therapeutics (MNPR) Set for Inclusion in Russell Indexes | MNPR Stock News - GuruFocus

Jun 03, 2025

Jun 03, 2025

Monopar Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes - The Manila Times

Jun 03, 2025

Jun 03, 2025

Monopar joins Russell 3000 and 2000 indexes, growth acknowledged By Investing.com - Investing.com UK

Jun 03, 2025

Jun 03, 2025

Monopar Therapeutics Added to Russell Indexes, Gains Access to $10.6T Benchmark Assets - Stock Titan

Jun 03, 2025

May 20, 2025

Piper Sandler Reaffirms Their Buy Rating on Monopar Therapeutics Inc (MNPR) - The Globe and Mail

May 20, 2025

May 18, 2025

(MNPR) Trading Advice - news.stocktradersdaily.com

May 18, 2025

May 17, 2025

Research Analysts Offer Predictions for MNPR Q2 Earnings - Defense World

May 17, 2025

May 14, 2025

Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock - The Globe and Mail

May 14, 2025

May 14, 2025

Monopar Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 14, 2025

May 13, 2025

Monopar (MNPR) Projects Financial Stability Through 2026 | MNPR Stock News - GuruFocus

May 13, 2025

May 13, 2025

Monopar Therapeutics reports Q1 EPS (38c), consensus (57c) - TipRanks

May 13, 2025

May 13, 2025

Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments - The Manila Times

May 13, 2025

May 13, 2025

Monopar Therapeutics SEC 10-Q Report - TradingView

May 13, 2025

May 08, 2025

2,037 Shares in Monopar Therapeutics Inc. (NASDAQ:MNPR) Acquired by JPMorgan Chase & Co. - Defense World

May 08, 2025

May 07, 2025

(MNPR) Proactive Strategies - news.stocktradersdaily.com

May 07, 2025

May 07, 2025

Monopar Therapeutics (MNPR) Showcases ALXN1840's Efficacy for Wi - GuruFocus

May 07, 2025

May 07, 2025

Monopar Therapeutics Inc expected to post a loss of 68 cents a shareEarnings Preview - TradingView

May 07, 2025

May 07, 2025

Monopar Therapeutics Highlights ALXN1840 Data at EASL 2025 - TipRanks

May 07, 2025

May 07, 2025

Monopar Therapeutics (MNPR) Showcases ALXN1840's Efficacy for Wilson Disease | MNPR Stock News - GuruFocus

May 07, 2025

May 07, 2025

Monopar Therapeutics (MNPR) Expected to Announce Quarterly Earnings on Thursday - Defense World

May 07, 2025

May 07, 2025

Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025 | MNPR Stock News - GuruFocus

May 07, 2025

May 07, 2025

Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025 - The Manila Times

May 07, 2025

May 02, 2025

Geode Capital Management LLC Acquires 24,530 Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) - Defense World

May 02, 2025

Apr 30, 2025

Why Monopar Therapeutics Inc. (MNPR) is Surging in 2025 - Insider Monkey

Apr 30, 2025

Apr 29, 2025

Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025 - The Manila Times

Apr 29, 2025

Apr 29, 2025

Why These 15 Healthcare Stocks Are Surging in 2025 - Insider Monkey

Apr 29, 2025

Apr 25, 2025

U.S. Severe Oral Mucositis Market Projected To Witness - openPR.com

Apr 25, 2025

Apr 22, 2025

(MNPR) Investment Analysis - news.stocktradersdaily.com

Apr 22, 2025

Apr 10, 2025

Monopar Therapeutics Inc. acquired worldwide license to ALXN-18 from Alexion Pharmaceuticals, Inc. for approximately $110 million. - marketscreener.com

Apr 10, 2025

Apr 06, 2025

(MNPR) Long Term Investment Analysis - news.stocktradersdaily.com

Apr 06, 2025

Apr 04, 2025

Major Shareholder Sells Big Chunk of Monopar Therapeutics Stock! - TipRanks

Apr 04, 2025

Apr 04, 2025

Monopar Therapeutics CEO Robinson sells $1.17 million in stock By Investing.com - Investing.com Canada

Apr 04, 2025

Apr 04, 2025

Jones Trading Reiterates “Hold” Rating for Monopar Therapeutics (NASDAQ:MNPR) - Defense World

Apr 04, 2025

Apr 04, 2025

HC Wainwright Issues Negative Forecast for MNPR Earnings - Defense World

Apr 04, 2025

Apr 03, 2025

What is HC Wainwright’s Forecast for MNPR FY2029 Earnings? - Defense World

Apr 03, 2025

Apr 02, 2025

Monopar Therapeutics downgraded to Hold from Buy at JonesResearch - TipRanks

Apr 02, 2025

Apr 02, 2025

We Think Monopar Therapeutics (NASDAQ:MNPR) Can Easily Afford To Drive Business Growth - Yahoo

Apr 02, 2025

Apr 02, 2025

Monopar Therapeutics (NASDAQ:MNPR) Receives “Buy” Rating from HC Wainwright - Defense World

Apr 02, 2025

Apr 01, 2025

Top 5 Small-cap Biotech Stocks of 2025 - Nasdaq

Apr 01, 2025

Apr 01, 2025

Monopar Therapeutics Stock Hits 52-Week High at $38.91 - MSN

Apr 01, 2025

Apr 01, 2025

Monopar Therapeutics Inc: Strategic Advancements and Promising Financial Projections Justify Buy Rating - TipRanks

Apr 01, 2025

Apr 01, 2025

Buy Rating for Monopar Therapeutics Inc: Strategic Advancements and Promising Financial Outlook - TipRanks

Apr 01, 2025

Mar 31, 2025

Monopar Therapeutics reports Q4 EPS ($2.23) vs. (60c) last year - TipRanks

Mar 31, 2025

Mar 31, 2025

Monopar Therapeutics sees cash runway through December 31, 2026 - TipRanks

Mar 31, 2025

Mar 31, 2025

Monopar Therapeutics Inc. (MNPR) reports earnings - Quartz

Mar 31, 2025

Mar 31, 2025

Monopar Therapeutics SEC 10-K Report - TradingView

Mar 31, 2025

Mar 31, 2025

Monopar Secures 2-Year Runway with $60M War Chest, Advances Wilson Disease Drug - Stock Titan

Mar 31, 2025

Mar 28, 2025

MNPR Stock Price and Chart — NASDAQ:MNPR - TradingView

Mar 28, 2025

Mar 21, 2025

Here's Why Momentum in Monopar Therapeutics (MNPR) Should Keep going - Yahoo Finance

Mar 21, 2025